{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:43:07Z","timestamp":1785595387316,"version":"3.56.0"},"reference-count":100,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Within the new psychoactive substances (NPS) scenario, several hundred different molecules, mostly including synthetic cannabinoids and cathinones, have been identified so far. The aims of the paper were to: (i) identify the number of synthetic cathinones mentioned in a range of psychonaut, NPS\u2010related, online sources; and (ii) describe the associated acute\/long term clinical scenario and the related treatment\/management plan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After about 18 months of operation and exclusion of false positives\/duplicates, some 4204 unique NPS molecules were included in the NPSfinder\u00ae crawling\/navigating software database. Most popular NPS included: 1265 psychedelic phenethylamines (30.1%; confidence interval [CI] 95%: 28.7\u201331.5%); 1253 synthetic cannabinoids (29.8%; CI 95%: 28.4\u201331.2%); 429 synthetic opioids (10.2%; CI 95%: 9.3\u201310.2%); and 171 synthetic cathinones (4.1%; CI 95% 3.5\u20134.7%). Conversely, the United Nations Office on Drugs and Crime and the European Monitoring Centre for Drugs and Drug Addiction databases respectively included 169 and 140 cathinones. Overall, the 3 databases reported some 222 synthetic cathinones, and 41 were uniquely identified by the NPSfinder\u00ae.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In terms of clinical scenarios, synthetic cathinone ingestion is initially associated with stimulant effects; however, psychopathological disturbances, violence, suicidal behaviour, hyperthermia, coma and death have also been described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The proportion of cathinones commented on by psychonaut fora appeared to be relatively small, and similar to those reported by both the United Nations Office on Drugs and Crime and European Monitoring Centre for Drugs and Drug Addiction. This may be associated with a recent significant decline in both cathinone\u2010related consumption and acute medical presentation. Due to their complex behavioural and medical toxicity issues, healthcare professionals should be, however, be educated to recognise the signs and symptoms of NPS, including synthetic cathinone, ingestion.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14132","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T07:44:46Z","timestamp":1572594286000},"page":"410-419","source":"Crossref","is-referenced-by-count":68,"title":["The clinical challenges of synthetic cathinones"],"prefix":"10.1111","volume":"86","author":[{"given":"Fabrizio","family":"Schifano","sequence":"first","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences University of Hertfordshire  Hatfield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Napoletano","sequence":"additional","affiliation":[{"name":"East London Foundation Trust (ELFT) Homerton University Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Arillotta","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences University of Hertfordshire  Hatfield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Zangani","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences University of Hertfordshire  Hatfield UK"},{"name":"Department of Health Sciences University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Gilgar","sequence":"additional","affiliation":[{"name":"Gabalfa Clinic, Cardiff and Vale NHS Health Board  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-0660","authenticated-orcid":false,"given":"Amira","family":"Guirguis","sequence":"additional","affiliation":[{"name":"Swansea University Medical School; Institute of Life Sciences; Swansea  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-817X","authenticated-orcid":false,"given":"John Martin","family":"Corkery","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences University of Hertfordshire  Hatfield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vento","sequence":"additional","affiliation":[{"name":"Addictions' Observatory (ODDPSS), Rome  Italy"},{"name":"Guglielmo Marconi University  Rome Italy"},{"name":"Department of Mental Health, ASL Roma 2  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2598"},{"key":"e_1_2_10_3_1","first-page":"284","article-title":"Sur un homologue de l'ephedrine","volume":"45","author":"Saem de Burnaga Sanchez J","year":"1929","journal-title":"Bull Soc Chim Fr"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.313"},{"key":"e_1_2_10_5_1","unstructured":"European Monitoring Centre for DrugsandDrug Addiction (EMCDDA) and the European Police Office (EUROPOL) \u201cEMCDDA\u2013Europol 2010 Annual report on the implementation of Council Decision 2005\/387\/JHA\u201d Lisbon May2011. (accessed on July 15th 2019)"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-017-0385-6"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20174"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfda.2017.04.001"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.4324\/9781315158082-11"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02145.x"},{"key":"e_1_2_10_11_1","first-page":"w14043","article-title":"Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling","volume":"145","author":"Liechti M","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.020"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.11.008"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.04.003"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.11.020"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_53"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12399"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4526-8"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0209-3"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.020"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2016.04.011"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-4985-6"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3108-7"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-010-3636-5"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1417"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03502.x"},{"key":"e_1_2_10_27_1","first-page":"386","article-title":"Beta\u2010cathinone derivatives\u2010\u2010a new generation of dangerous psychostimulant \"designer drugs\"","volume":"70","author":"Zawilska JB","year":"2013","journal-title":"Przegl Lek"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-2070-x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_61"},{"key":"e_1_2_10_30_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).EMCDDA\u2013Europol 2017 Annual Report on the Implementation of Council Decision 2005\/387\/JHA; Publications Office of the European Union: Luxembourg 2018a; Available from:http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/9282\/20183924_TDAN18001ENN_PDF.pdf(accessed on July 15th 2019)"},{"key":"e_1_2_10_31_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).European Drug Report2019: Trends and Developments.EMCDDA Lisbon June 2019. Available from:http:\/\/www.emcdda.europa.eu\/publications\/edr\/trends-developments\/2019(accessed on July 15th 2019)"},{"key":"e_1_2_10_32_1","unstructured":"United Nations Office on Drugs and Crime (UNODC).World Drug Report 2018 Volume 3\u2014Analysis of Drug Markets: Opiates Cocaine Cannabis Synthetic Drugs; United Nations Office on Drugs and Crime: Vienna Austria 2018a; Available online:https:\/\/www.unodc.org\/wdr2018\/(accessed on July 15th 2019)"},{"key":"e_1_2_10_33_1","unstructured":"United Nations.World Drug Report2019. Available from:https:\/\/wdr.unodc.org\/wdr2019\/(accessed on July 15th 2019)"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2299"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2566"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/cyber.2014.0486"},{"key":"e_1_2_10_37_1","first-page":"1","article-title":"New\/emerging psychoactive substances and associated psychopathological consequences","volume":"22","author":"Schifano F","year":"2019","journal-title":"Psychol Med"},{"key":"e_1_2_10_38_1","first-page":"19","article-title":"Bath salts and synthetic cannabinoids: a review","volume":"19","author":"Cheng S","year":"2012","journal-title":"Am Acad Emerg Med"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-4953-1"},{"key":"e_1_2_10_40_1","first-page":"160","article-title":"The analysis of admissions to the emergency Department of the Psychiatric Hospital in Bielsko\u2010Bia\u0142a connected with psychotic disorders induced by psychoactive drug use","volume":"18","author":"Kaizer\u2010B\u0119dkowska MJ","year":"2018","journal-title":"Psychiatr Psychol Kliniczna 2018"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2012.06.005"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-015-1212-4"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bks136"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318266c70c"},{"key":"e_1_2_10_45_1","first-page":"47368","article-title":"The new designer drug wave: a clinical, toxicological, and legal analysis","author":"Abbott R","year":"2015","journal-title":"J Psychoactive Drugs"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2015.09.002"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2016.1271424"},{"issue":"1","key":"e_1_2_10_48_1","article-title":"Prolonged hypoglycemia in the setting of synthetic cathinone abuse","volume":"3","author":"Ramirez Berlioz A","year":"2019","journal-title":"J Endocrine Soc"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.10.012"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2012.01.005"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2013.04.017"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.05.048"},{"key":"e_1_2_10_53_1","first-page":"140","article-title":"(2015). Catatonia in medically ill patients; an evidence\u2010based medicine (EBM) monograph for psychosomatic medicine practice","volume":"30","author":"Denysenko L","year":"2015","journal-title":"Europ Assoc Psychosom Medicine"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-015-0024-7"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.210"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/1556-4029.12202"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-011-0196-9"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-011-0199-6"},{"key":"e_1_2_10_59_1","first-page":"268","article-title":"Synthetic cathinones related fatalities: an update","volume":"22","author":"Zaami S","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2016.1172594"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05213-3"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-019-00020-2"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-20-08417.1998"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/JAN.0000000000000252"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5067-5"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2017.11.015"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X15666161117151148"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1353094"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116662635"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2016.03.005"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-6-52"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3182915dce"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.10.007"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.014"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2018.1448867"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2016.1166508"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2017.12.003"},{"key":"e_1_2_10_78_1","first-page":"223","article-title":"Designer drugs in psychiatric practice \u2010 a review of the literature and the recent situation in Hungary","volume":"15","author":"Szily E","year":"2013","journal-title":"Neuropsychopharmacol Hung"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.17116\/sudmed201760418-20"},{"key":"e_1_2_10_80_1","first-page":"1","article-title":"Recent changes in drug abuse scenarios: the new\/novel psychoactive substances (NPS) phenomenon","volume":"8","author":"Schifano F","year":"2018","journal-title":"Brain Sci"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JAA.0000541487.41149.71"},{"key":"e_1_2_10_82_1","first-page":"1","article-title":"Synthetic drug intoxication in children: recognition and management in the emergency department","volume":"15","author":"Shah R","year":"2018","journal-title":"Pediatr Emerg Med Pract"},{"key":"e_1_2_10_83_1","first-page":"1","article-title":"Novel psychoactive substances: the pharmacology of stimulants and hallucinogens","volume":"4","author":"Schifano F","year":"2016","journal-title":"Exp Rev Clin Pharmacol"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2366"},{"key":"e_1_2_10_85_1","volume-title":"Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances","author":"Abdulrahim D","year":"2015"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-011-0193-z"},{"key":"e_1_2_10_87_1","unstructured":"TOXBASE 2019.Available from:http:\/\/www.npis.org\/toxbase.html(accessed on July 24th 2019)"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2431"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.05.008"},{"key":"e_1_2_10_90_1","unstructured":"United Nations Office on Drugs and Crime (UNODC).UNODC World Drug Report 2018: The range of NPS has never been greater.2018b. Available from:https:\/\/www.unodc.org\/LSS\/announcement\/Details\/fa879924-6bdf-4ba2-a8eb-a87185d26439(accessed on July 15th 2019)"},{"key":"e_1_2_10_91_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).EMCDDA publishes latest insights into NPS in Europe 2018b; Available from: emcdda:http:\/\/www.emcdda.europa.eu\/news\/2018\/emcdda-publishes-latest-insights-into-nps-in-europe_en(accessed on July 15th 2019)"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2018.1494277"},{"key":"e_1_2_10_93_1","unstructured":"Home Office.Seizures of drugs in England and Wales financial year ending 2018 Statistical Bulletin 26\/18. November. London: Home Office 2018a. Available at:https:\/\/www.gov.uk\/government\/statistics\/seizures-of-drugs-in-england-and-wales-financial-year-ending-2018(accessed on July 15th 2019)"},{"key":"e_1_2_10_94_1","unstructured":"Home Office.Drug Misuse: Findings from the 2017\/18 Crime Survey for England and Wales. Statistical Bulletin 14\/18. July. London: Home Office 2018b. Available at:https:\/\/www.gov.uk\/government\/statistics\/drug-misuse-findings-from-the-2017-to-2018-csew(accessed on July 15th 2019)"},{"key":"e_1_2_10_95_1","unstructured":"Police Services in Northern Ireland (PSNI).Police Recorded Drug Seizures and Arrests in Northern Ireland: Update to 31 March 2019. Belfast: Police Service of Northern Ireland 30 May2019. Available at:https:\/\/www.psni.police.uk\/inside-psni\/Statistics\/drug-seizure-statistics\/(accessed on July 15th 2019)"},{"key":"e_1_2_10_96_1","unstructured":"Scottish Government.Drug seizures and offender characteristics 2017\u201018. 19 March. Edinburgh: Justice Analytical Services Scottish Government 2019. Available at:https:\/\/www.gov.scot\/publications\/drug-seizures-offender-characteristics-2017-18\/(accessed on July 15th 2019)"},{"key":"e_1_2_10_97_1","unstructured":"Public Health England (PHE).Substance misuse treatment for adults: statistics 2017 to 2018. London: Public Health England 2018a. Available at:https:\/\/www.gov.uk\/government\/statistics\/substance-misuse-treatment-for-adults-statistics-2017-to-2018(accessed on July 15th 2019)"},{"key":"e_1_2_10_98_1","unstructured":"Public Health England (PHE).Substance misuse treatment for young people: statistics 2017 to 2018. 6 December. London: Public Health England 2018b. Available at:https:\/\/www.gov.uk\/government\/statistics\/substance-misuse-treatment-for-young-people-statistics-2017-to-2018(accessed on July 15th 2019)"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1177\/0036933018760761"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2012.07.011"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1177\/0960327117698542"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14132","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T20:32:37Z","timestamp":1693859557000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/bcp.14132"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14132","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]}}}